Atrium Therapeutics

Atrium Therapeutics is a Montreal-based biotechnology company dedicated to developing innovative therapies for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded on pioneering research from the Montreal Heart Institute, the company focuses on the molecular mechanisms underlying electrical and structural remodeling in the heart. Their approach involves targeting specific ion channels, such as the inward rectifier potassium channel (IK1), and microRNA pathways to restore normal heart rhythm. Atrium Therapeutics aims to address the significant unmet need for safer and more effective rhythm-control treatments that avoid the side effects of current anti-arrhythmic drugs. The company was launched with investment from AmorChem and continues to advance its pre-clinical pipeline.